Background: Dementia is a progressive neurodegenerative syndrome affecting memory, cognition and behaviour, with approximately 57 million people affected worldwide.[1] Alzheimer’s disease, the most common form, involves cholinergic dysfunction, oxidative stress, neuroinflammation and neuronal degeneration. Current drugs provide mainly symptomatic relief and may cause adverse effects, highlighting interest in plant-derived neuroprotective agents. Mucuna pruriens seeds contain L-DOPA, flavonoids, phenolics, alkaloids and saponins with reported antioxidant, anti-inflammatory and neuroprotective effects. Materials and Methods: Methanolic extract of Mucuna pruriens seeds (MEMPS) was prepared by Soxhlet extraction and subjected to phytochemical screening. Anti-dementia activity was evaluated in atropine-induced memory impairment in Wistar rats (200–220 g; n=6/group). Animals received atropine (10 mg/kg, s.c.) for 7 days with donepezil (3 mg/kg, p.o.) or MEMPS (200 and 400 mg/kg, p.o.). Memory was assessed on days 1, 2, 4 and 7 using Elevated Plus Maze and Passive Avoidance tests. Results: MEMPS produced dose- and time-dependent improvements in transfer latency and step-through latency compared with the disease control. The 400 mg/kg dose showed effects approaching those of donepezil by day 7. Phytochemical screening revealed alkaloids, flavonoids, phenolics, tannins, saponins, glycosides, steroids and carbohydrates. Conclusion: MEMPS demonstrated promising anti-dementia activity against atropine-induced cognitive impairment, potentially through antioxidant and cholinergic mechanisms, warranting further mechanistic, biochemical and toxicological studies.
No takes yet. Share an insight, caveat, or question.
Munawar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: